Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
Authors not listed
Universidad de Almeria · 2026
Abstract
The goal of this clinical trial is to learn if tributyrin can help prevent or mitigate cognitive decline in individuals with mild Alzheimer's disease (AD). The trial will also examine the safety and effects of tributyrin on inflammation and gut microbiota. The main questions it aims to answer are:
Does tributyrin reduce inflammation and neurodegeneration markers? How does tributyrin affect gut microbiota and intestinal permeability? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no active ingredient) to evaluate its effectiveness.
Participants will:
Take tributyrin or a placebo every day for 12 weeks. Undergo assessments of cognitive function, blood markers (such as NfL and pTau217), and gut health.
The findings are expected to provide insight into the potential of tributyrin as a preventive intervention for Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2026). Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain. <em>Universidad de Almeria</em>. https://clinicaltrials.gov/study/NCT06797817
Vancouver
Anonymous. Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain. Universidad de Almeria. 2026.
BibTeX
@misc{anon2026Tribut,
title = {Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain},
author = {Anonymous},
journal = {Universidad de Almeria},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of South Florida 2026
Open access · US-GOV
A Postbiotics Intervention to Improve Cognitive Function in Older Adults With Mild Cognitive Impairment (Phase 1)
Anne B. Newman 2023
Open access · US-GOV
Reducing Inflammation for Greater Health Trial: The RIGHT Study
Zhejiang Hospital 2025
Open access · US-GOV
A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease
Yanbu Ke 2025
Open access · US-GOV
A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease
Baylor College of Medicine 2022
Open access · US-GOV
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Universidad Santo Tomas, Chile 2026
Open access · US-GOV